A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.

Abstract

Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths among men in the western world. In the evolution of second generation anti-androgens, enzalutamide, a novel androgen-receptor signaling inhibitor, has emerged targeting multiple steps within the androgenic stimulation pathway. This review discusses what is currently known of the mechanisms surrounding castration resistant prostate cancer development and the current human clinical trials to determine whether enzalutamide presents a new hope for men with advanced prostate cancer. The issues of therapy resistance, withdrawal effects and cross-resistance are briefly touched upon.

Metadata

Authors/Creators:	Greasley, R. Khabazhaitajer, M. Rosario, D.J. https://orcid.org/0000-0002-9086-3592
Copyright, Publisher and Additional Information:	© 2015 Greasley et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Keywords:	MDV3100; androgen receptor; anti-androgen; enzalutamide; metastatic castrate resistant prostate cancer
Dates:	Accepted: 7 September 2014 Published (online): 12 June 2015 Published: 12 June 2015
Institution:	The University of Sheffield
Academic Units:	The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals
Depositing User:	Symplectic Sheffield
Date Deposited:	09 Aug 2016 10:17
Last Modified:	09 Aug 2016 10:17
Published Version:	http://dx.doi.org/10.2147/CMAR.S50585
Status:	Published
Publisher:	Dove Medical Press
Refereed:	Yes
Identification Number:	https://doi.org/10.2147/CMAR.S50585
Related URLs:	Author

CORE (COnnecting REpositories)

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.

Abstract

Metadata

Download

Published Version

Export

Statistics